Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Axovant Sciences Ltd. | 99,285,714 | reported | 18 Dec 2018 | tx 1+10,000,000 |
| Adaptive Biotechnologies Corp | 33,493,708 | reported | 28 Jan 2020 | tx 10+36,981,607−41,644,506 |
| Urovant Sciences Ltd. | 22,860,013 | reported | 19 Jun 2019 | tx 11+2,738,213 |
| BridgeBio Pharma, Inc. | 18,555,375 | reported | 27 Jun 2025 | tx 1−3,500,000 |
| FIRST DATA CORP | 10,144,738 | reported | 13 Apr 2016 | tx 10+43,500,128−43,500,128 |
| Zentalis Pharmaceuticals, Inc. | 3,943,284 | reported | 01 Dec 2020 | tx 1−500,000 |
| Wayfair Inc. | 1,751,436 | reported | 03 Nov 2014 | tx 6+855,439 |
| APi Group Corp | 196,000 | reported | 03 Jan 2022 | tx 2+200,000 |
| PROCEPT BioRobotics Corp | 0 | reported | 17 Sept 2021 | tx 7+4,599,750−4,199,750 |
| Editas Medicine, Inc. | 0 | reported | 08 Feb 2016 | tx 11+5,459,616−8,888,888 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 27 Jun 2025 | SALE | BridgeBio Pharma, Inc. | 3,500,000 | 44.00 USD | |
| 03 Jan 2022 | PURCHASE | APi Group Corp | 4,000 | 1000.00 USD | derivanomaly |
| 03 Jan 2022 | PURCHASE | APi Group Corp | 196,000 | 1000.00 USD | derivanomaly |
| 17 Sept 2021 | CONVERSION | PROCEPT BioRobotics Corp | 3,407,028 | — | |
| 17 Sept 2021 | PURCHASE | PROCEPT BioRobotics Corp | 400,000 | 35.00 USD | first after silenceanomaly |
| 17 Sept 2021 | CONVERSION | PROCEPT BioRobotics Corp | 113,737 | — | |
| 17 Sept 2021 | CONVERSION | PROCEPT BioRobotics Corp | 678,985 | — | |
| 17 Sept 2021 | CONVERSION | PROCEPT BioRobotics Corp | 678,985 | 0.00 USD | deriv |
| 17 Sept 2021 | CONVERSION | PROCEPT BioRobotics Corp | 113,737 | 0.00 USD | deriv |
| 17 Sept 2021 | CONVERSION | PROCEPT BioRobotics Corp | 3,407,028 | 0.00 USD | deriv |
| 01 Dec 2020 | SALE | Zentalis Pharmaceuticals, Inc. | 500,000 | 50.50 USD | |
| 28 Jan 2020 | SALE | Adaptive Biotechnologies Corp | 4,912,899 | 24.98 USD | |
| 01 Jul 2019 | CONVERSION | Adaptive Biotechnologies Corp | 2,007,740 | — | |
| 01 Jul 2019 | CONVERSION | Adaptive Biotechnologies Corp | 290,572 | — | |
| 01 Jul 2019 | CONVERSION | Adaptive Biotechnologies Corp | 15,524,350 | — | |
| 01 Jul 2019 | CONVERSION | Adaptive Biotechnologies Corp | 18,908,945 | — | |
| 01 Jul 2019 | PURCHASE | Adaptive Biotechnologies Corp | 250,000 | 20.00 USD | anomaly |
| 01 Jul 2019 | CONVERSION | Adaptive Biotechnologies Corp | 18,908,945 | — | deriv |
| 01 Jul 2019 | CONVERSION | Adaptive Biotechnologies Corp | 290,572 | — | deriv |
| 01 Jul 2019 | CONVERSION | Adaptive Biotechnologies Corp | 2,007,740 | — | deriv |
| 01 Jul 2019 | CONVERSION | Adaptive Biotechnologies Corp | 15,524,350 | — | deriv |
| 19 Jun 2019 | PURCHASE | Urovant Sciences Ltd. | 4,957 | 8.17 USD | |
| 18 Jun 2019 | PURCHASE | Urovant Sciences Ltd. | 6,706 | 8.21 USD | |
| 17 Jun 2019 | PURCHASE | Urovant Sciences Ltd. | 6,541 | 8.53 USD | |
| 21 May 2019 | PURCHASE | Urovant Sciences Ltd. | 9,995 | 8.52 USD |
2 purchases reported after at least 12 months of silence — most recent on 17 Sept 2021.